Canine Leishmaniasis Management Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Canine leishmaniasis Prevention, Canine Leishmaniasis Treatment), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Veterinary Clinics and Pharmacies, and Others) and Region

Canine Leishmaniasis Management Market size was valued at US$ 388.5 million in 2023 and is projected to reach US$ 432.8 million by 2029, at a CAGR of 5.2% owing to the increasing pet ownership, and rising incidence of canine leishmaniasis are projected to drive the market over the forecast period 2024-2030. Canine leishmaniasis is an incurable multisystemic disease caused by the parasite, Leishmania infantum, which is transferred through the bite of a sandfly in tropical and subtropical countries, but direct transmission between dogs, and from pregnant dogs to their puppies, exists. 

The rising incidence of canine leishmaniasis plays a pivotal role in driving the revenues. The incidence of canine leishmaniasis is rising gradually worldwide. For instance, research suggests that the highest estimated ranged from 50 to 100 cases per 1000 dogs annually and were concentrated in the southeastern and southwestern regions of Spain, as well as the Balearic Islands. This increased burden of this disease drives the demand for the development of advanced treatment and diagnosis options. Diagnosis of this disease is often determined via serology, with quantitative serologic tests such as immunofluorescence assays or ELISA as confirmation. Treatment options are limited but the major protocols used for the treatment of leishmaniasis in dogs include the use of N-methylglucamine antimoniate or Miltefosine in combination with allopurinol.

Moreover, rising government regulations are another powerful driver of the canine leishmaniasis management market. As health concerns about animal increases across the globe, the government is imposing several strict guidelines, which in turn necessitate the development of canine leishmaniasis management options. A nonprofit scientific association, LeishVet, has created regulations, primarily designed to assist veterinary clinicians in the management of canine leishmaniosis by suggesting standardized and rational approaches to the diagnosis, treatment, follow-up, control, and prevention of canine leishmaniosis. This strict regulation ultimately drives the growth of the canine leishmaniosis management market.

However, factors such as limited treatment options and lack of awareness pose significant challenges to the growth of the market. Meanwhile, the rise in research and development activities presents a significant opportunity for the growth. Several key manufacturers are announcing launches to strengthen their market position.

Key Developments:

On March 2024, Zendal Group launches Spanish National Research Council (CSIC) developed DNA based vaccine for canine leishmaniasis.